{"id":"W2136139191","doi":"10.1177/1352458508097299","title":"Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results","year":2008,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Institutes of Health","keywords":"Medicine; Tolerability; Immunogenicity; Interferon beta-1a; Multiple sclerosis; Confidence interval; Adverse effect; Internal medicine; Clinical endpoint; Clinical trial; Antibody; Gastroenterology; Immunology; Interferon beta","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00387568,0.001276615,0.001772656,0.0003961578,0.0003156204,0.0007614698,0.0008553662,0.001509504,0.001799363],"category_scores_gemma":[0.002408171,0.0006390456,0.001375434,0.0003389987,0.0008956199,0.0008656934,0.0004126063,0.002669401,0.000589261],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006041287,"about_ca_system_score_gemma":0.0005107037,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003558199,"about_ca_topic_score_gemma":0.0003310485,"domain_scores_codex":[0.9989735,0.0005658042,0.0000653686,0.0001545084,0.0001405005,0.0001003194],"domain_scores_gemma":[0.9978411,0.0005821395,0.000729013,0.0002402263,0.0001568989,0.0004504956],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.738843,0.06728254,0.02255103,0.0009439429,0.002014239,0.0004741136,0.000554908,0.002290489,0.06958639,0.0001264824,0.001319433,0.09401333],"study_design_scores_gemma":[0.26825,0.68861,0.03053536,0.00004046307,0.0006252414,0.0007970755,0.00005399149,0.0008282431,0.008519841,0.00008037025,0.001617991,0.00004147147],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965106,0.001851345,0.0004847948,0.0001176719,0.00003473766,0.0004241306,0.0002236574,0.00002917192,0.0003239204],"genre_scores_gemma":[0.9939743,0.001336324,0.001453008,0.0002521874,0.000129101,0.0008655614,0.00079695,0.0000202441,0.001172393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00387568,"threshold_uncertainty_score":0.02049679,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1209235769177282,"score_gpt":0.3048185937232836,"score_spread":0.1838950168055554,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}